Biography
Stifelman earned his undergraduate degree in zoology from the University of Massachusetts and his medical degree from the Albert Einstein College of Medicine in the Bronx, NY. [3]
Stifelman joined HackensackUMC in 2016 after working at NYU Langone Medical Center, where he was Professor of Urology at the NYU School of Medicine, [4] Director of the Robotic Surgery Center, and Chief of Urology Services at Tisch Hospital. [5]
He completed his internship and residency in general surgery, as well as his urology residency at Columbia Presbyterian Medical Center, NY, serving as chief resident in urology during his final year. [3] He received his fellowship in endourology and laparoscopy at Weill Cornell Medical Center, New York, NY, and is board certified in urology. [2]
Stifelman currently serves as Professor and Inaugural Chair of Urology, Hackensack Meridian School of Medicine; Chair of Urology, Hackensack Meridian Hackensack University Medical Center; Director of Urologic Oncology at John Theurer Cancer Center; and Director of Robotic Surgery, Hackensack Meridian Health.
From 2009 to 2012, he was a co-investigator in a Vivus-sponsored study on Avanafil for erectile dysfunction after prostatectomy, and in the NIH/Gen-Probe-sponsored EDRN PCA3 Validation Trial. [6] In 2015, he was a co-investigator in the ADAPT Phase 3 trial on dendritic cell immunotherapy for advanced renal cell carcinoma. [7] Since 2016, he has been the principal investigator in the TARPAN Study on the use of the AirSeal system in robotic partial nephrectomy. [8] He is also the principal investigator of a study on prostasomes as a diagnostic tool for prostate cancer, ongoing since 2018. [9]
Stifelman’s current translational research interests include prostasomes for prostate cancer detection, creating a biorepository of urologic cancers, and amniotic membrane nerve regeneration.
Research
CLARIX Clinical Trial
Stifelman serves as the principal investigator of a prospective, randomized controlled clinical trial at Hackensack University Medical Center evaluating the efficacy of CLARIX® CORD 1K, a cryopreserved umbilical cord allograft, in enhancing functional recovery following bilateral nerve-sparing robot-assisted radical prostatectomy (RARP). [10] The trial, titled Prospective, Controlled Study Evaluating Recovery of Potency and Continence Following Robot-Assisted Radical Prostatectomy with and without Cryopreserved Umbilical Cord Allograft, enrolls 100 male participants randomized in a 1:1 ratio to undergo either standard RARP or RARP with intraoperative CLARIX application. [11]
The trial builds upon retrospective findings presented by Stifelman's colleague Ravi Munver at the 2018 World Congress of Endourology, which suggested that CLARIX may support earlier functional recovery post-surgery. [10]
Herpes Simplex Virus (HSV) Gene Therapy Research
In addition to his work in robotic surgery, Stifelman collaborates on translational research involving the use of herpes simplex virus (HSV) as a vector for gene therapy. This line of investigation focuses on developing targeted drug delivery systems to treat chronic urologic conditions, such as neurogenic detrusor overactivity and other lower urinary tract dysfunctions. [12]
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
